Metabolomics and its Applications in Cancer Cachexia

Cui, Pengfei; Li, Xiaohua; Huang, Caihua; Li, Qinxi; Lin, Donghai

doi:10.3389/fmolb.2022.789889

Cited by 18 publications

(14 citation statements)

References 113 publications

(113 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For biomarker studies with muscle tissue, blood, and urine samples, various analytical approaches were used, including nuclear resonance spectrometry, gas chromatography-mass spectrometry, and liquid chromatography-mass spectrometry. The levels of metabolites, such as phenylalanine, asymmetric dimethylarginine (ADMA), paraxanthine, 3-hydroxybutyrate, lysoPC 18:2, lysoPC 16:1, hexadecanoic acid (palmitic acid), and octadecanoic acid (stearic acid), were elevated in patients with cachexia and weight loss ( 72 ). Among them, ADMA has been identified as a potential therapeutic target for cachexia ( 73 ).…”

Section: Methodsmentioning

confidence: 99%

“…Intensity of exercise was set at three levels (≤2,000 steps, >2,000 steps/<8,000 steps, and ≥8,000 steps) and was tailored to each patient based on their baseline average number of steps per day during the screening period. The median age of the patients was 75 years [70][71][72][73][74][75][76][77][78][79][80][81][82][83][84], and 12 (40%) patients met the criteria for cachexia at inclusion. Twenty-eight (93%) patients participated in all courses, resulting in 6 (15%) patients with increased indoor activities and 15 (52%) patients with increased outdoor activities.…”

Section: Clinical Interventional Study For Cancer Cachexiamentioning

confidence: 99%

See 1 more Smart Citation

The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review

Yamada¹,

Takayama²

2023

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background and Objective Cancer cachexia presents with weight loss, anorexia, and fatigue and worsens the prognosis and quality of life of cancer patients. We aimed to summarize the current relevant discourse in the literature about cancer cachexia in the setting of non-small cell lung carcinoma and the possible current and future treatments. Methods We conduct a narrative review of the literature on the landscape of cancer cachexia in the context of non-small cell lung cancer, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances. Key Content and Findings The need for appropriate intervention for cancer cachexia is increasing as the prognosis of patients with advanced non-small cell lung cancer is improving with advances in treatment. Tumor cells play a role in the pathogenesis of cachexia, where they release factors that elicit the production of inflammatory cytokines by the immune system resulting in decreased appetite, abnormal energy metabolism, and skeletal muscle degeneration. Comorbid chronic lung diseases are associated with pulmonary cachexia and sarcopenia and commonly occur in the context of lung cancer, further contributing to the increased incidence of cachexia in patients with lung cancer. Currently, a ghrelin-like agonist, anamorelin, is approved for the treatment of cancer cachexia and is used in clinical practice in Japan. The role that nutritional and exercise therapies can play as added treatments must be further explored. Conclusions Cancer cachexia remains a poorly understood phenomenon, and awareness must be raised through educational activities for health care providers and patient family members. In addition, new therapeutics targeting cancer cachexia, such as GDF-15 antibodies, are in development, and further progress is expected.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Clinical Interventional Study For Cancer Cachexiamentioning

confidence: 99%

The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review

Yamada¹,

Takayama²

2023

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…The novel omics studies are deepening our knowledge about cancer cachexia (Loumaye and Thissen, 2017;Paccielli Freire et al, 2020;Cui et al, 2022), increasing the list of potential biomarkers for an early diagnosis. By focalizing on both general and cancerspecific cachexia inducing factors, these approaches will allow the development of novel targeted therapies depending on the cancer types (Paccielli Freire et al, 2020).…”

Section: Biomarkers For Cancer Cachexia: An Unmet Medical Needmentioning

confidence: 99%

“…By focalizing on both general and cancerspecific cachexia inducing factors, these approaches will allow the development of novel targeted therapies depending on the cancer types (Paccielli Freire et al, 2020). More specifically, metabolomics studies allow to identify non-invasive markers of cachexia such as the already mentioned microRNAs (Donzelli et al, 2020), sphingolipids (Morigny et al, 2020), lipoprotein and amino acids changes (O'Connell et al, 2021), highlighting the crucial role of new technologies in this context (Loumaye and Thissen, 2017;Paccielli Freire et al, 2020;Cui et al, 2022).…”

Section: Biomarkers For Cancer Cachexia: An Unmet Medical Needmentioning

confidence: 99%

Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene

Ferrara

Samaden

Ruggieri

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cachexia is a devastating syndrome associated with the end-stage of several diseases, including cancer, and characterized by body weight loss and severe muscle and adipose tissue wasting. Although different cancer types are affected to diverse extents by cachexia, about 80% of all cancer patients experience this comorbidity, which highly reduces quality of life and response to therapy, and worsens prognosis, accounting for more than 25% of all cancer deaths. Cachexia represents an urgent medical need because, despite several molecular mechanisms have been identified, no effective therapy is currently available for this devastating syndrome. Most studies focus on skeletal muscle, which is indeed the main affected and clinically relevant organ, but cancer cachexia is characterized by a multiorgan failure. In this review, we focus on the current knowledge on the multiple tissues affected by cachexia and on the biomarkers with the attempt to define a chronological pathway, which might be useful for the early identification of patients who will undergo cachexia. Indeed, it is likely that the inefficiency of current therapies might be attributed, at least in part, to their administration in patients at the late stages of cachexia.

show abstract

“…Moreover, a standardized method for the diagnosis and treatment of cachexia is lacking. Nevertheless, developments in organoids, single‐cell technology, and metabolomics 300 will help us in further exploring the relationship among tumors, the TME, cancer cachexia, and multiple organs homeostasis imbalance and to determining core signals and molecular mechanisms. The integrated application of different methods for the treatment of cancer and cancer cachexia, including diet and exercise, has deepened our understanding of the relationship between cancer cachexia and multiple organs homeostasis imbalance.…”

Section: Summary and Prospect Of The Futurementioning

confidence: 99%

Targeting cancer cachexia: Molecular mechanisms and clinical study

Wang

Lin

et al. 2022

MedComm

View full text Add to dashboard Cite

Cancer cachexia is a complex systemic catabolism syndrome characterized by muscle wasting. It affects multiple distant organs and their crosstalk with cancer constitute cancer cachexia environment. During the occurrence and progression of cancer cachexia, interactions of aberrant organs with cancer cells or other organs in a cancer cachexia environment initiate a cascade of stress reactions and destroy multiple organs including the liver, heart, pancreas, intestine, brain, bone, and spleen in metabolism, neural, and immune homeostasis. The role of involved organs turned from inhibiting tumor growth into promoting cancer cachexia in cancer progression. In this review, we depicted the complicated relationship of cancer cachexia with the metabolism, neural, and immune homeostasis imbalance in multiple organs in a cancer cachexia environment and summarized the treatment progress in recent years. And we discussed the molecular mechanism and clinical study of cancer cachexia from the perspective of multiple organs metabolic, neurological, and immunological abnormalities. Updated understanding of cancer cachexia might facilitate the exploration of biomarkers and novel therapeutic targets of cancer cachexia.

show abstract

Metabolomics and its Applications in Cancer Cachexia

Cited by 18 publications

References 113 publications

The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review

The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review

Cancer cachexia as a multiorgan failure: Reconstruction of the crime scene

Targeting cancer cachexia: Molecular mechanisms and clinical study

Contact Info

Product

Resources

About